A new state-of-the-art high-intensity focused ultrasound (HIFU) machine, the JC200 manufactured by Haifu Technology Ltd, has been installed at the Churchill Hospital, giving Oxford University Hospitals (OUH) patients access to the latest in this innovative technology.
An earlier version of this device has been used for clinical indications such as uterine fibroids and adenomyosis, as well as for previous research trials of cancers involving the kidney, liver and pancreas. This new machine allows the OUH team to continue to expand the clinical programme in treatment of non-cancerous tumours including uterine fibroids in addition to developing research programmes potentially involving cancers of the liver, pancreas, breast and the musculoskeletal system including sarcoma.
The new JC200, CE-marked for tumour therapy, was gifted to OUH by the Chinese manufacture, Haifu Technology Ltd., and replaces a similar but older HIFU machine of the same name, which had been installed in 2010 and was used to gain CE-marking for the device but was reaching end of life. Charitable donations including funds from the Focused Ultrasound Foundation have helped cover the installation and maintenance costs of the new device. Dr Rustam Rea (OUH Deputy Chief Medical Officer and Director of Clinical Improvement) officially opened the new unit on 30th January 2026 with the clinical HIFU team.
Prof David Cranston, Emeritus Clinical Director of HIFU, said: “This technology holds enormous promise for greater clinical expansion, as well as further research. Studies in fibroid patients have shown that outcomes with HIFU are similar to surgery with faster recovery and fewer adverse effects.”
Dr Paul Lyon, OUH Consultant Radiologist and Clinical Director of the Oxford HIFU service, said: “This upgrade is fantastic news for our patients. The improved technology in the latest JC200 device means treatments can be quicker and smoother for the patients. It’s a major upgrade in terms of both diagnostic and therapeutic performance. In addition to enabling expansion of the existing clinical service it also offers great potential for cutting-edge oncology clinical research.”